SCHEMBL5018989

SCHEMBL5018989

CN[C@H](C(=O)O)[C@H](O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.46
CES1 P23141 2/20 0.46
AKR1C3 P42330 2/20 0.46
AKR1C2 P52895 2/20 0.46
MMP1 P03956 1/20 0.45
MMP2 P08253 1/20 0.45
MMP3 P08254 1/20 0.45
MMP7 P09237 1/20 0.45
MMP9 P14780 1/20 0.45
MMP13 P45452 1/20 0.45
SLC1A3 P43003 1/20 0.43
SLC1A2 P43004 1/20 0.43
SLC1A1 P43005 1/20 0.43
CNR2 P34972 1/20 0.41
GRM8 O00222 1/20 0.41
GRM4 Q14833 1/20 0.41
ACP3 P15309 1/20 0.41
FFAR1 O14842 3/20 0.40
PSEN1 P49768 1/20 0.40
PSEN2 P49810 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5018966 1.00 CES2 (0.46) CES2CES1AKR1C3AKR1C2MMP1
SCHEMBL12475032 0.84 CES2 (0.44) CES2CES1AKR1C3AKR1C2MMP1
SCHEMBL5018925 0.84 CES2 (0.44) CES2CES1AKR1C3AKR1C2MMP1
SCHEMBL12475033 0.84 CES2 (0.44) CES2CES1AKR1C3AKR1C2MMP1
SCHEMBL5018914 0.84 AKR1C3 (0.49) CES2CES1AKR1C3AKR1C2MMP1
SCHEMBL31466845 0.80 CYP2C9 (0.43) ALDH1A1MAPT
SCHEMBL27298058 0.80 CYP2C9 (0.43) ALDH1A1MAPT
SCHEMBL7431162 0.79 ADRA2C (0.57) ALDH1A1MAPT
SCHEMBL7431159 0.79 ADRA2C (0.57) ALDH1A1MAPT
SCHEMBL5024093 0.79 PPARG (0.49) CES2CES1AKR1C3AKR1C2MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178490-B2 Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof REMPEX PHARMACEUTICALS, INC. (US) 2012-05-15 US disclosed
US-20100152098-A1 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF MPEX PHARMACEUTICALS, INC. (US) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152098-A1 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF ABCB11, ABCB1, SLC47A1 CES2 831/4885CES1 1206/4885AKR1C3 3794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.